Bengaluru and San Jose-based data analytics firm Tredence has acquired US-based KMK Consulting, aiming to strengthen its presence in healthcare and life sciences analytics. The financial terms of the acquisition were not disclosed. Tredence anticipates that this vertical will contribute approximately 25% to its overall revenue by 2028.The acquisition is part of Tredence’s strategy to capitalize on the growing adoption of artificial intelligence (AI) within the pharmaceutical industry, which reportedly spends around $250 billion annually on research and development (R&D) and an equal amount on commercialization. Shashank Dubey, co-founder and chief revenue officer of Tredence, highlighted the rapid AI-led transformation in the sector, noting that analytics and AI services for life sciences are projected to grow at a compound annual growth rate (CAGR) of 20%-25% in the coming years.Founded in 2000, KMK Consulting has established itself by working with eight of the world’s top ten pharmaceutical companies, specializing in areas such as commercial analytics, patient analytics, market access, real-world evidence, and market research. Tredence views this acquisition as a merger of complementary strengths, combining KMK’s extensive pharmaceutical expertise with Tredence’s AI engineering capabilities and data platforms.The deal also enhances Tredence’s access to major pharmaceutical clients, as KMK already serves a significant portion of the global pharma market. Dubey emphasized that enterprises are increasingly seeking partners capable of building production-grade AI systems rather than merely experimental projects, indicating a shift in the market’s needs.Founded in 2013, Tredence focuses on helping large businesses optimize their data usage through AI-powered software and tools. The company is on track to achieve a 45% growth this year, with a revenue target of $1 billion by 2030, driven by both organic growth and acquisitions. Dubey mentioned that Tredence may consider a fresh fundraising round in 2027 and is open to the possibility of an initial public offering (IPO) in the future, although this remains an option rather than a necessity. Additionally, Tredence is exploring acquisitions beyond healthcare, with sectors like communications, media, and insurance also in focus.
